Effective for dates of service
on or after June 1, 2012, we will implement important changes to the list of
services and drugs that require precertification for most commercial
AmeriHealth New Jersey members (Comprehensive Major Medical [CMM] members are
excluded).*
The following
precertification requirements will be added for these members in all settings:
- cardiac radiology (stress
echocardiography, resting transthoracic echocardiography, and transesophageal
echocardiography);
- potentially cosmetic
procedures (please refer to the complete list below);
- pain management procedures
(paravertebral facet joint injections, transforaminal epidural injections,
epidural injections);
- additional medical
infusion/injectable drugs (please refer to the complete list of additions
listed below);
- cataract surgery;
- cochlear implant surgery;
- hyperbaric oxygen;
- uvulopalatopharyngoplasty (UPPP or
UP3).
The following
precertification requirements will be removed for these members in all
settings:
- sleep studies
- cardiac rehabilitation
- pulmonary
rehabilitation
It is very important that providers use
the NaviNet® web portal to verify
member-specific requirements or refer to the most current precertification
requirement lists on our website. Failure to obtain precertification
for any of the services or drugs that require it may result in a reduction in
payment or nonpayment for the services not precertified.
Please call 1-800-275-2583 if you have any questions about these
upcoming changes.
|
Blepharoplasty/ptsosis repair
|
Hair transplant
|
Rhinoplasty
|
Breast: reconstruction, reduction,
augmentation, mammoplasty, mastopexy, insertion, and removal of breast
implants
|
Injectable dermal fillers
|
Rhytidectomy
|
Canthopexy/canthoplasty
|
Keloid removal
|
Scar revision
|
Cervicoplasty
|
Labiaplasty
|
Sex reassignment surgery
|
Chemical peels
|
Lipectomy, liposuction, or any other
excess fat removal procedure
|
Skin closures including: skin
grafts, skin flaps, and tissue grafts
|
Dermabrasion
|
Orthognathic surgery procedures
including, but not limited to: bone graft, genioplasty, osteoplasty,
mentoplasty, osteotomies
|
Surgery for varicose veins,
including perforatos amd sclerotherapy
|
Excision of excessive skin and/or
subcutaneous tissue
|
Otoplasty
|
Surgical treatment of
gynecomastia
|
Genetically and bio-engineered skin
substitutes for wound care
|
|
|
Abraxane?
|
Flolan?
|
Jevtana?
|
Alimta?
|
Folotyn?
|
Nulojix?
|
Alpha 1 inhibitors (Aralast NPTM, GlassiaTM,
Prolastin? C, Zemaira?)
|
Gammaplex? (IVIG)
|
Provenge?
|
ArzerraTM
|
HalavenTM
|
Psoriasis/rheumatoid arthritis
(Actemra?)
|
Benlysta?
|
Hemophilia factors
|
Remodulin?
|
C1 esterase inhibitors
(Berinert?, Cinryze?)
|
Herceptin? DM1†
|
Soliris?
|
Enzyme replacement (Lumizyme?, Replagal?†, Uplyso?†, VPRIV?)
|
Istodax?
|
YervoyTM
|
|
Kalbitor?
|
MakenaTM
|
Stelara?
|
Lucentis?
|
OmaproTM†
|
XgevaTM
|
Macugen?
|
Prolia?
|
Xolair?
|
*This change is pending approval from the New Jersey
Department of Banking and Insurance for Small Employer Health (SEH) members.
†This drug is pending approval from the U.S. Food and Drug
Administration.